BACTROBAN
LOE ApproachingNDANASALOINTMENT
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
BACTROBAN by GSK is clinical pharmacology pharmacokinetics following single or repeated intranasal applications of 0. First approved in 1995.
Drug data last refreshed 21m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTROBAN (mupirocin) is a topical antibiotic ointment administered intranasally that inhibits bacterial protein synthesis by binding to isoleucyl transfer-RNA synthetase. It is indicated for nasal eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization as part of institutional infection control programs. The drug demonstrates bactericidal activity with minimal systemic absorption in adults and no cross-resistance with other antimicrobial classes.
LOE Approaching
Product approaching loss of exclusivity with limited commercial expansion opportunities; team focus likely shifting to cost optimization and market transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following single or repeated intranasal applications of 0.2 gram of BACTROBAN NASAL 3 times daily for 3 days to 5 healthy adult male subjects, no evidence of systemic absorption of mupirocin was demonstrated. The dosage regimen used in this study was for…
Worked on BACTROBAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.